-- Jiangsu Hengrui Pharmaceuticals' (SHA:600276, HKG:1276) recorded a 22% rise in attributable profit for the first quarter of 2026 to 2.28 billion yuan from 1.87 billion yuan a year prior, according to a Wednesday Hong Kong bourse filing.
Earnings per share jumped to 0.34 yuan from 0.30 yuan in the corresponding period of the previous fiscal year.
Operating revenue climbed 13% to 8.14 billion yuan from 7.21 billion yuan in the year-ago period.